Plain-English translation of NCT07325539 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a three-part treatment combination for patients with nasopharyngeal cancer (a type of throat cancer) that has returned or spread to other parts of the body. The combination includes , an immune-boosting drug that helps your body fight cancer, plus chemotherapy and targeted low-dose radiation. Researchers want to see whether this combination works better than previous treatments and how safe it is.
Nasopharyngeal cancer that comes back or spreads is very difficult to treat, and current options have limited success. This trial is testing whether the medication, combined with chemotherapy and radiation, can help more patients by working together to attack the cancer in multiple ways.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive low-dose radiation therapy combined with regular infusions of and chemotherapy for 4 to 6 cycles (about 2 to 3 months). After that, you will continue receiving the medication alone until your cancer stops responding or side effects become too difficult to manage. You will have regular clinic visits for blood tests, imaging scans, and check-ups to monitor how well the treatment is working and how you are tolerating it.
AI-generated summary from trial data · Aug 2, 2026 · Not medical advice
China